Abstract
No public abstract is available from the verified source records.
Anne Marie Reimer Jensen, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, Negar Aliabadi, Kristoffer G Skaarup, Daniel Modin, Kira Hyldekær Janstrup, Brian L Claggett, Carsten S Larsen, Lykke Larsen, Lothar Wiese, Michael Dalager-Pedersen, Matias G Lindholm, Maria Dons, Katrine F Bernholm, Filip S Davidovski, Lisa S Duus, Camilla I Ottosen, Anne B Nielsen, Julie H Borchsenius, Caroline Espersen, Guldas Köse, Frederik H Fussing, Lars Køber, Scott D Solomon, Jens Ulrik Stæhr Jensen, Cyril Jean-Marie Martel, Bradford D Gessner, Claudia Schwarz, Elisa Gonzalez, Mette Skovdal, Pingping Zhang, Tor Biering-Sørensen
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Respiratory syncytial virus infection in elderly and high-risk adults
10.1056/nejmoa043951 · 2005
Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis
10.1093/infdis/jiz059 · 2020
Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults
10.1093/cid/ciy991 · 2019
Burden of respiratory syncytial virus-associated hospitalizations in US adults, October 2016 to September 2023
10.1001/jamanetworkopen.2024.44756 · 2024
Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature
10.1086/525263 · 2008
Epidemiology and immediate indirect effects of respiratory viruses in lung transplant recipients: a 5-year prospective study
10.1111/ajt.14042 · 2017
Impact of RSV infection in transplant and immunocompromised population: incidence and co-infections: retrospective analysis of a single centre
10.3390/jcm14134803 · 2025
Incidence of respiratory syncytial virus-associated hospitalization among adults in Ontario, Canada, 2017–2019
10.1093/infdis/jiaf343 · 2025
Respiratory syncytial virus sequelae among adults in high-income countries: a systematic literature review and meta-analysis
10.1007/s40121-024-00974-7 · 2024
Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries
10.1093/ofid/ofad513 · 2023
Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults
10.1056/nejmoa2213836 · 2023
Respiratory syncytial virus prefusion F protein vaccine in older adults
10.1056/nejmoa2209604 · 2023
Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older
10.1001/jamanetworkopen.2025.8322 · 2025
RSV vaccine effectiveness against hospitalization among US adults aged 60 years or older during 2 seasons
10.1001/jama.2025.15896 · 2025
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis
10.1016/s0140-6736(24)01738-0 · 2024
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case-control study
10.1016/s1473-3099(25)00546-8 · 2026
Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: an interventional cohort study
10.1016/j.cmi.2025.09.013 · 2026
Respiratory syncytial virus vaccination in allogeneic hematopoietic stem cell transplant recipients
10.1001/jamanetworkopen.2025.33828 · 2025
RSV prefusion F vaccine for prevention of hospitalization in older adults
10.1056/nejmoa2509810 · 2026
A pragmatic individually randomized trial to evaluate bivalent RSV prefusion F protein-based vaccine effectiveness for preventing RSV hospitalizations in adults aged 60 years or above (DAN-RSV): rationale and trial design
10.1016/j.ahj.2025.07.068 · 2025
The Danish civil registration system
10.1177/1403494810387965 · 2011
Two-sided confidence intervals for the single proportion: comparison of seven methods
10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · 1998
Estimated vaccine effectiveness for respiratory syncytial virus-related lower respiratory tract disease
10.1001/jamanetworkopen.2024.50832 · 2024
Durability of respiratory syncytial virus vaccine effectiveness among US veterans
10.1001/jamainternmed.2025.6355 · 2026
Antibody response to respiratory syncytial virus vaccination in immunocompromised persons
10.1001/jama.2024.25395 · 2025
Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees
10.1016/j.ajt.2025.03.025 · 2025
Neutralizing antibody response to the AreXvy respiratory syncytial virus vaccine in lung transplant recipients: assessment against reference and seasonal strains
10.3390/vaccines13040398 · 2025
Immunogenicity and safety of the bivalent respiratory syncytial virus prefusion F subunit vaccine in immunocompromised or renally impaired adults
10.3390/vaccines13030328 · 2025
A phase 1/2 study of a respiratory syncytial virus prefusion F vaccine with and without adjuvant in healthy older adults
10.1093/infdis/jiac189 · 2022
Estimated Medicaid spending on original and citrate-free adalimumab from 2014 through 2021
10.1001/jamainternmed.2022.6299 · 2023
Prevalence of immunosuppression among US adults
10.1001/jama.2023.28019 · 2024
Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in leukaemia
10.1016/s1473-3099(25)00365-2 · 2026
Efficacy, immunogenicity, and safety of the bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine in older adults over 2 RSV seasons
10.1093/cid/ciaf061 · 2026
Efficacy, immunogenicity, and safety of the bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine in older adults over 2 RSV seasons
10.1093/cid/ciaf061 · doi-reference
Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in leukaemia
10.1016/s1473-3099(25)00365-2 · doi-reference
Prevalence of immunosuppression among US adults
10.1001/jama.2023.28019 · doi-reference
Estimated Medicaid spending on original and citrate-free adalimumab from 2014 through 2021
10.1001/jamainternmed.2022.6299 · doi-reference
A phase 1/2 study of a respiratory syncytial virus prefusion F vaccine with and without adjuvant in healthy older adults
10.1093/infdis/jiac189 · doi-reference
Immunogenicity and safety of the bivalent respiratory syncytial virus prefusion F subunit vaccine in immunocompromised or renally impaired adults
10.3390/vaccines13030328 · doi-reference
Neutralizing antibody response to the AreXvy respiratory syncytial virus vaccine in lung transplant recipients: assessment against reference and seasonal strains
10.3390/vaccines13040398 · doi-reference
Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees
10.1016/j.ajt.2025.03.025 · doi-reference
Antibody response to respiratory syncytial virus vaccination in immunocompromised persons
10.1001/jama.2024.25395 · doi-reference
Durability of respiratory syncytial virus vaccine effectiveness among US veterans
10.1001/jamainternmed.2025.6355 · doi-reference
Estimated vaccine effectiveness for respiratory syncytial virus-related lower respiratory tract disease
10.1001/jamanetworkopen.2024.50832 · doi-reference
Two-sided confidence intervals for the single proportion: comparison of seven methods
10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · doi-reference
The Danish civil registration system
10.1177/1403494810387965 · doi-reference
A pragmatic individually randomized trial to evaluate bivalent RSV prefusion F protein-based vaccine effectiveness for preventing RSV hospitalizations in adults aged 60 years or above (DAN-RSV): rationale and trial design
10.1016/j.ahj.2025.07.068 · doi-reference
RSV prefusion F vaccine for prevention of hospitalization in older adults
10.1056/nejmoa2509810 · doi-reference
Respiratory syncytial virus vaccination in allogeneic hematopoietic stem cell transplant recipients
10.1001/jamanetworkopen.2025.33828 · doi-reference
Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: an interventional cohort study
10.1016/j.cmi.2025.09.013 · doi-reference
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case-control study
10.1016/s1473-3099(25)00546-8 · doi-reference
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis
10.1016/s0140-6736(24)01738-0 · doi-reference
RSV vaccine effectiveness against hospitalization among US adults aged 60 years or older during 2 seasons
10.1001/jama.2025.15896 · doi-reference
Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older
10.1001/jamanetworkopen.2025.8322 · doi-reference
Respiratory syncytial virus prefusion F protein vaccine in older adults
10.1056/nejmoa2209604 · doi-reference
Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults
10.1056/nejmoa2213836 · doi-reference
Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries
10.1093/ofid/ofad513 · doi-reference
Respiratory syncytial virus sequelae among adults in high-income countries: a systematic literature review and meta-analysis
10.1007/s40121-024-00974-7 · doi-reference
Incidence of respiratory syncytial virus-associated hospitalization among adults in Ontario, Canada, 2017–2019
10.1093/infdis/jiaf343 · doi-reference
Impact of RSV infection in transplant and immunocompromised population: incidence and co-infections: retrospective analysis of a single centre
10.3390/jcm14134803 · doi-reference
Epidemiology and immediate indirect effects of respiratory viruses in lung transplant recipients: a 5-year prospective study
10.1111/ajt.14042 · doi-reference
Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature
10.1086/525263 · doi-reference
Burden of respiratory syncytial virus-associated hospitalizations in US adults, October 2016 to September 2023
10.1001/jamanetworkopen.2024.44756 · doi-reference
Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults
10.1093/cid/ciy991 · doi-reference
Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis
10.1093/infdis/jiz059 · doi-reference
Respiratory syncytial virus infection in elderly and high-risk adults
10.1056/nejmoa043951 · doi-reference